Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Pfizer, Eli Lilly report detailed results from late-stage study of NGF inhibitor tanezumab in osteoarthritis pain

firstwordpharmaOctober 25, 2018

Tag: Pfizer , NGF , tanezumab

PharmaSources Customer Service